The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000563369p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
16/04/2026
Date registered
Help: Date registered
4/05/2026
Date last updated
Help: Date last updated
4/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
New physiotherapy treatment for older people with lumbar spinal stenosis that causing leg symtpms
Scientific title
Exploring the potentail benefits of multimodal intervention for older adults with lumbar spinal stenosis causing neurogenic claudication: A single-case experimental design pilot study
Additional trial identifiers [1] 305380 0
none
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Lumbar spinal stenosis 341561 0
Neurogenic claudication 341654 0
Condition category
Condition code
Musculoskeletal 337638 337638 0 0
Other muscular and skeletal disorders
Neurological 337745 337745 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Derived from a biopsychosocial framework, treatments encompass psychologically informed patient education, lifestyle modification, neuropathic pain-specific exercises, manual therapy and exercise (e.g., stationary exercise bike) to improve general cardiovascular function. Based on initial physiotherapy assessment, participants will receive 7 weekly one-to-one physiotherapy sessions, tailored to individual clinical presentation. Patient education will included in each physiotherapy sessions as part of the intervention (~10 minutes per visit, varying depending on participant's clinical presentation), inclduing a clear biopsychosocial explanation of their problem and outline of a comprehensive treatment plan, advice on avoiding excessive sedentary behaviour, activity/sporting technique modification, manual handling advice, strategies to address contributing factors related to sleep hygiene and lifestyle choices, and management of comorbidities if indicated. Participants will be prescribed a progressive general graded exercise programme matched to their clinical presentation. To unload neural tissue and optimise neural mechanics and load tolerance, physiotherapists will prescribe specific movement (e.g., mobility exercises targeting thoracic/hip extension) and muscle performance exercises (e.g., abdominal/hip extension muscle activation and strengthening exercises) tailored to each participant’s clinical presentation. Participants will be instructed to perform the prescribed exercises at home as frequently as needed to manage their pain. Exercise will be progressed as sensitivity of the affected nerves improves. When neural compromise is not evident, physiotherapists will provide manual therapy (e.g., passive joint mobilisation techniques to imporve lumbar flexion and thoracic/hip extension dysfunction, neural gliding and tensioning techniques) and exercises (e.g., neural gliding exercise) to optimise neural mechanics by directly mobilising the nerve. A qualified and registered physiotherapist who is trained in delivering this multimodal intervention will provide treatments for all participants. Each treatment session will last for 30 minutes whereas the initial consult will take 60 minutes. For home exercises, participants will be provided with written exercise instructions and diagrams and an exercise diary to monitor their adherence and any adverse events. Treatment attendance will be recorded to assess adherence to the intervention.
Intervention code [1] 333811 0
Treatment: Other
Intervention code [2] 333868 0
Lifestyle
Description of the comparator or control
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345127 0
Leg and back pain intensity while walking will be assessed the Brief Pain Inventory. Participants will rate on four separate numerical rating scales (NRS, 0 = “no pain”, 10 = “worst pain you can imagine”) for pain at its most intense over the last week, pain at its least intense over the last week, pain of average intensity over the last week, and pain right now. The scores will be averaged to calculate a final pain intensity score out of 10. This will be assessed as a composite outcome.
Timepoint [1] 345127 0
There are baseline, and two 7-day follow-up phases in this study: one immediately after the completion of the intervention phase (follow-up I) and another five weeks later (follow-up II).
Primary outcome [2] 345128 0
Swiss Spinal Stenosis (SSS) questionnaire (12-item version) has a 7-item symptom severity subscale and a 5-item physical function subscale.The SSS score ranges from 12 to 55 points, with higher scores indicating higher levels of self-reported disability.
Timepoint [2] 345128 0
There are baseline, and two 7-day follow-up phases in this study: one immediately after the completion of the intervention phase (follow-up I) and another five weeks later (follow-up II).
Secondary outcome [1] 460558 0
Pain interference will be assessed by seven items of the Brief Pain Inventory – Pain Interference scale. Participants will rate the extent to which pain interfered with their life on a 0–10 NRS (0 = “Does not interfere”, 10 = “Completely interferes”) in seven activity domains: general activity, normal work, walking ability, enjoyment of life, relations with others, mood, and sleep, with higher score indicating greater interference of pain in daily life. The scores will be averaged to determine a final pain interference score out of 10.
Timepoint [1] 460558 0
There are baseline, and two 7-day follow-up phases in this study: one immediately after the completion of the intervention phase (follow-up I) and another five weeks later (follow-up II).

Eligibility
Key inclusion criteria
• people who have been diagnosed as having lumbar spinal stenosis (LSS) and share diagnostic imaging results (magnetic resonance imaging or computed tomography) showing narrowing of the central canal, lateral recess, and/or foramen
• the presence of at least one of these clinical signs of LSS: (1) leg symptoms worsened by walking and relieved by sitting; (2) symptoms worsened by lumbar extension and relieved by flexion; and/or (3) leg pain relieved by leaning forward on a shopping cart while walking.
• ability to read/write English
• ability to walk outside without an assistive device
• limitation of walking due to LSS
• ability to engage in mild exercise


Minimum age
60 Years
Maximum age
80 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• previous surgery for LSS or lumbar fusion
• cauda equina symptoms
• advised by a physician not to engage in physical exercise
• history of metastatic cancer
• severe peripheral artery disease
• any neurologic disorders that affect the ability to walk
• previous hip joint replacement including hemiarthroplasty
• body mass index > 30
• osteoporosis

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The primary and secondary outcomes will be analysed by comparing the daily-measured pain severity, SSS scores and pain interference during the baseline phase with those during the intervention and follow-up I and II phases. To determine whether reliable changes in outcome measures across different phases indicate a systematic intervention effect, we will use two methods: visual inspection and non-overlap effect sizes.

Visual inspection involves examining the graphed data to determine data stability and to establish whether there is a causal relation between the intervention and the outcomes using within-phase and between-phase analyses. Within-phase analysis examines the stability and pattern of the data in each phase. Between-phase analysis examines the data overlap between phases and the consistency of any intervention effect.

For within-phase visual analysis, the median, range, stability, and trend of data within each phase ware calculated. The stability criterion for each phase is achieved when 80% of datapoints in that phase are within ±25% of the phase’s median. Trend is defined as a systematic increase or decrease in the outcome measures over time. Trend is calculated as the slope of a regression line through the data over time. A positive slope is an increasing trend in the data in the opposite direction of the treatment effect, whereas a negative slope is a decreasing trend in the data in the direction of the treatment effect.

The between-phase visual analysis depends on four features of data to interpret the changes in the data, and whether the intervention causes those changes. The first two features are the change in the mean and the change in the median of the primary and secondary outcomes across phases. The third feature is the relative change in level, defined as a discontinuity of data from the second half of one phase to the first half of the next phase. The fourth feature is the change in trend of the data across phases. The between phase analyses will compare the baseline phase to the intervention, follow-up I and follow-up II phases.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 309749 0
University
Name [1] 309749 0
UNSW School of Health Sciences Seed Funding
Country [1] 309749 0
Australia
Primary sponsor type
University
Name
University of New South Wales
Address
Country
Australia
Secondary sponsor category [1] 324469 0
None
Name [1] 324469 0
Address [1] 324469 0
Country [1] 324469 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 309505 0
The University of New South Wales Research Ethics Committee A
Ethics committee address [1] 309505 0
Ethics committee country [1] 309505 0
Australia
Date submitted for ethics approval [1] 309505 0
11/05/2026
Approval date [1] 309505 0
Ethics approval number [1] 309505 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 114390 0
Dr Wei-Ju Chang
Address 114390 0
Health Translational Hub, Level 6 North, UNSW SYDNEY NSW 2052
Country 114390 0
Australia
Phone 114390 0
+61 2 9348 1633
Fax 114390 0
Email 114390 0
Contact person for public queries
Name 114391 0
Wei-Ju Chang
Address 114391 0
Health Translational Hub, Level 6 North, UNSW SYDNEY NSW 2052
Country 114391 0
Australia
Phone 114391 0
+61 2 9348 1633
Fax 114391 0
Email 114391 0
Contact person for scientific queries
Name 114392 0
Wei-Ju Chang
Address 114392 0
Health Translational Hub, Level 6 North, UNSW SYDNEY NSW 2052
Country 114392 0
Australia
Phone 114392 0
+61 2 9348 1633
Fax 114392 0
Email 114392 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
When can requests for individual participant data be made (start and end dates)?
From:
At the end of the study
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.